Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34263
Abstract: High‐risk neuroblastoma patients with end‐induction residual disease commonly receive post‐induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to… read more here.
Keywords: end induction; patients end; risk neuroblastoma; high risk ... See more keywords
3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.11.025
Abstract: INTRODUCTION Prognosis of neuroblastoma patients is very diverse, indicating the need for more accurate prognostic parameters. The excretion of catecholamine metabolites by most neuroblastomas is used for diagnostic purposes, but their correlation with prognosis has… read more here.
Keywords: risk; prognosis; high risk; neuroblastoma patients ... See more keywords
Non-inferiority of fragmented care for high-risk pediatric neuroblastoma patients: a single institution analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Pediatric hematology and oncology"
DOI: 10.1080/08880018.2021.1922557
Abstract: Pediatric neuroblastoma (NB) patients receive multi-modal therapy and may experience care fragmented among multiple institutions with a significant travel burden, which has been associated with poor outcomes for some adult cancers. We hypothesized that fragmented… read more here.
Keywords: analysis; high risk; fragmented care; neuroblastoma patients ... See more keywords
Abstract LB-300: Natural antibodies to non-human glycans Neu5Gc and alpha-gal correlate with outcome of high-risk neuroblastoma patients treated with dinutuximab on COG ANBL0032 and ANBL0931
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-lb-300
Abstract: Immunotherapy with ch14.18 (dinutuximab) has significantly improved the survival of high-risk neuroblastoma patients, though late relapses and allergic reaction remain concerning. N-glycolylneuraminic acid (Neu5Gc) and galactose alpha-1,3-galactose (α-gal) are glycans present in most mammals except… read more here.
Keywords: neuroblastoma patients; high risk; natural antibodies; risk neuroblastoma ... See more keywords
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4910-8
Abstract: BackgroundIndirect evidence suggesting the immunosensitivity/immunogenicity of neuroblastoma is accumulating. The aims of this study were to investigate the immune landscape of neuroblastoma and to evaluate the in vivo immunogenicity of the NY-ESO-1 tumor antigen in… read more here.
Keywords: immunogenicity; immunogenicity eso; neuroblastoma patients; antigen ... See more keywords
Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.10550
Abstract: 10550Background: So far, and apart from minor adaptations, high-risk neuroblastoma patients have been treated uniformly by not taking biological features of the tumor into consideration. To mend th... read more here.
Keywords: risk; based post; prediction based; neuroblastoma patients ... See more keywords
Phosphoserine phosphatase as an indicator for survival through potentially influencing the infiltration levels of immune cells in neuroblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2022.873710
Abstract: Introduction: Metabolic deregulation, a hallmark of cancer, fuels cancer cell growth and metastasis. Phosphoserine phosphatase (PSPH), an enzyme of the serine metabolism pathway, has been shown to affect patients’ prognosis in many cancers but its… read more here.
Keywords: phosphoserine phosphatase; potentially influencing; psph; expression ... See more keywords
Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.845757
Abstract: Background Pyroptosis, as an inflammatory form of cell death, is involved in many physiological and pathological processes. Neuroblastoma is the most common extra-cranial solid tumor in children. In this study, the relationship between pyroptosis and… read more here.
Keywords: gene network; prognosis; pyroptosis; neuroblastoma patients ... See more keywords
Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.878457
Abstract: Background Infiltrating immune cells have been reported as prognostic markers in many cancer types. We aimed to evaluate the prognostic role of tumor-infiltrating lymphocytes, namely CD3+ T cells, CD8+ cytotoxic T cells and memory T… read more here.
Keywords: pathology; digital pathology; neuroblastoma patients; cd3 cd8 ... See more keywords
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14235802
Abstract: Simple Summary The treatment of high-risk neuroblastoma patients with anti-GD2 antibodies has improved survival, and it is an established treatment strategy; however, many patients still experience a late relapse. One disadvantage of passive immunotherapy is… read more here.
Keywords: risk neuroblastoma; high risk; anti gd2; neuroblastoma patients ... See more keywords
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092535
Abstract: Simple Summary Naxitamab (Danyelza®) is a newly FDA-approved humanized anti-GD2 antibody for the treatment of relapsed/refractory in the bone/bone-marrow-only compartment high-risk neuroblastoma. In our center, we had the unique opportunity to use Naxitamab in patients… read more here.
Keywords: risk neuroblastoma; neuroblastoma patients; high risk; complete remission ... See more keywords